
## Satabdi Chatterjee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12188240/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk of overactive bladder associated with cholinesterase inhibitors in dementia. Journal of the American Geriatrics Society, 2022, 70, 820-830.	2.6	1
2	Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs and Aging, 2022, 39, 453-465.	2.7	4
3	Opioid Prescribing Among Outpatients with Rheumatoid Arthritis. Pain Medicine, 2021, 22, 2224-2234.	1.9	4
4	Prevalence and Factors Associated with Cumulative Anticholinergic Burden Among Older Long-Stay Nursing Home Residents with Overactive Bladder. Drugs and Aging, 2021, 38, 311-326.	2.7	1
5	Application of machine learning in predicting hospital readmissions: a scoping review of the literature. BMC Medical Research Methodology, 2021, 21, 96.	3.1	46
6	Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia. Drugs and Aging, 2021, 38, 593-602.	2.7	5
7	The Costs and Healthcare Resource Utilization Associated with Anticholinergic Burden in Long-Stay Nursing Home Residents with Overactive Bladder in the US. PharmacoEconomics - Open, 2021, 5, 727-736.	1.8	4
8	Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Research in Social and Administrative Pharmacy, 2020, 16, 329-335.	3.0	16
9	Anticholinergic medications and risk of dementia in older adults: Where are we now?. Expert Opinion on Drug Safety, 2020, 19, 1251-1267.	2.4	9
10	Prevalence and predictors of non-evidence based proton pump inhibitor use among elderly nursing home residents in the US. Research in Social and Administrative Pharmacy, 2017, 13, 358-363.	3.0	45
11	Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy, 2017, 37, 287-296.	2.6	9
12	Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. Drugs and Aging, 2017, 34, 691-700.	2.7	21
13	Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. Journal of the American Geriatrics Society, 2016, 64, 1492-1497.	2.6	28
14	Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case–Control Study. Journal of the American Geriatrics Society, 2016, 64, 394-400.	2.6	41
15	Antimuscarinic Medication Use in Elderly Patients with Overactive Bladder. Drugs and Aging, 2016, 33, 755-763.	2.7	11
16	Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. Journal of Comparative Effectiveness Research, 2016, 5, 461-473.	1.4	6
17	Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. American Journal of Geriatric Psychiatry, 2016, 24, 485-495.	1.2	24
18	Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 678-686.	1.9	10

SATABDI CHATTERJEE

#	Article	IF	CITATIONS
19	Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. Psychiatric Services, 2015, 66, 1333-1340.	2.0	18
20	Risk of Hospitalization and Use of First- Versus Second-Generation Antipsychotics Among Nursing Home Residents. Psychiatric Services, 2014, 65, 781-788.	2.0	11
21	Risk of Pneumonia in Elderly Nursing Home Residents Using Typical Versus Atypical Antipsychotics. Annals of Pharmacotherapy, 2013, 47, 464-474.	1.9	21
22	Risk of Death in Dual-eligible Nursing Home Residents Using Typical or Atypical Antipsychotic Agents. Medical Care, 2012, 50, 961-969.	2.4	26
23	Risk of Falls and Fractures in Older Adults Using Atypical Antipsychotic Agents: A Propensity Score–Adjusted, Retrospective Cohort Study. American Journal of Geriatric Pharmacotherapy, 2012, 10, 83-94.	3.0	33
24	Comparative Risk of Cerebrovascular Adverse Events in Community-Dwelling Older Adults using Risperidone, Olanzapine and Quetiapine. Drugs and Aging, 2012, 29, 807-817.	2.7	24
25	An analysis of the warning letters issued by the FDA to pharmaceutical manufacturers regarding misleading health outcomes claims. Pharmacy Practice, 2012, 10, 194-198.	1.5	7
26	Prevalence and Predictors of Anticholinergic Agents in Elderly Outpatients with Dementia. American Journal of Geriatric Pharmacotherapy, 2011, 9, 434-441.	3.0	32
27	Prevalence and Predictors of Anticholinergic Medication Use in Elderly Nursing Home Residents with Dementia. Drugs and Aging, 2010, 27, 987-997.	2.7	48